Table 1.
Literature review on anti-BRAF therapies used in solid tumors with BRAF gene fusions.
| Case | Histologic diagnosis | Age/Gender | Sample source | BRAF fusion | Therapy | PFS(month) | Response | OS(month) |
|---|---|---|---|---|---|---|---|---|
| Chew et al. (17) | Melanoma | 40/F | Lung metastasis | SKAP2-BRAF | Trametinib | 3 m | PR | 4 m |
| Menzies et al. (18) | Melanoma | 47/F | Brain metastasis | PPFIBP2-BRAF | Trametinib | NA | PR | 8 m |
| Melanoma | 65/M | Subcutaneous calf metastasis | KIAA1549-BRAF | Trametinib | NA | SD (enlargement) |
8 m | |
| Subbiah et al. (19) | Spindle cell neoplasm | 55/F | Primary tumor | KIAA1549-BRAF | Bevacizumab + temsirolimus + sorafenib | NA | SD (reduction) |
NA |
| Isaacson et al. (20) | Papillary urothelial carcinoma | 69/M | Liver metastasis | NRF1-BRAF | Trametinib | 3 m | PR | NA |
| del Bufalo et al. (21) | Gangliogliomas | 2/M | Primary tumor | KIAA1549-BRAF +BRAF V600E | Vemurafenib | NA | NA (reduction) |
NA |
| Zhu YC et al. (10) | Lung cancer | 60/M | Primary tumor | TRIM24-BRAF | Vemurafenib | 3.5 m | PR | 9 m |
| Wang CY et al. (14) | Lung cancer | 66/M | Pleural metastasis | LIMD1-BRAF | Trametinib | 7.4 m | PR | NA |
M, male; F, female; PFS, progression-free survival; OS, overall survival; PR, partial response; SD, stable disease; NA, not available.